ENANTA PHARMACEUTICALS INC — fact timeline

ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2026 results: revenue $17.2 million, net income Net loss ... $13.1 million, EPS loss of $0.45 per diluted common share.

“multiple value-driving milestones over the coming year.” Fiscal Second Quarter Ended March 31, 2026 Financial Results Total revenue for the three months ended March 31, 2026 was $17.2 million and consisted of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), AbbVie’s treatment for hepatitis C virus, compared to $14.9 million for”

ENANTA PHARMACEUTICALS INC reported fiscal quarter ended March 31, 2024 results: revenue $17.1 million, EPS a loss of $1.47 per diluted common share. Guidance reaffirmed.

“chronic diseases with a second program this year.” Fiscal Second Quarter Ended March 31, 2024 Financial Results Total revenue for the three months ended March 31, 2024 was $17.1 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $17.8 million for”

ENANTA PHARMACEUTICALS INC shareholders approved Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2024 Fiscal Year at the 2024-03-06 meeting.

“Proposal No. 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2024 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2024. Votes For Votes Against Abstain Broker Non-Votes 14,571,800 27,373 2,076,083 0”

ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2024-03-06 meeting.

“Proposal No. 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a “say-on-pay” vote. Votes For Votes Against Abstain Broker Non-Votes 12,306,697 3,196,342 16,183 1,156,034”

ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 975,000 shares at the 2024-03-06 meeting.

“Proposal No. 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares. Votes For Votes Against Abstain Broker Non-Votes 8,076,566 7,421,300 21,356 1,156,034”

ENANTA PHARMACEUTICALS INC shareholders approved Election of Three Class II Directors at the 2024-03-06 meeting.

“Proposal No. 1: To Elect Three Class II Directors to Serve until the 2027 Annual Meeting or until their respective successors are elected and qualified. The stockholders re-elected the following individuals as Class II directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Yujiro S. Hata 13,127,063 2,392,002 1,156,191 Kristine Peterson 12,994,324 2,524,741 1,156,191 Terry C. Vance 12,169,732 3,209,519 1,296,005”

Nathaniel S. Gardiner departed as Senior Vice President and General Counsel at ENANTA PHARMACEUTICALS INC.

“On December 19, 2023, Nathaniel S. Gardiner, age 70, Senior Vice President and General Counsel of Enanta Pharmaceuticals, Inc., announced his intention to retire on or before March 31, 2024.”

ENANTA PHARMACEUTICALS INC updated its fiscal fourth quarter and year ended September 30, 2023 guidance (lowered).

“On November 20, 2023, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2023.”

ENANTA PHARMACEUTICALS INC reported fiscal third quarter ended June 30, 2023 results: revenue $18.9 million, net income Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share, EPS $1.86 per diluted common share. Guidance reaffirmed.

“Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million WATERTOWN, Mass., Aug. 7, 2023 – Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral”

ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2023 results: revenue $17.8 million, net income net loss of $37.7 million, or a loss of $1.79 per diluted common share, EPS a loss of $1.79 per diluted common share.

“Total revenue for the three months ended March 31, 2023 was $17.8 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $18.7 million for the three months ended March 31, 2022. Research and development expenses totaled $43.5 million for the three months ended March 31, 2023, compared to $42.1 million for the three months ended March 31, 2022. The increase was primarily due to the timing of clinical trial expenses in our virology programs. General and administrative expenses totaled $13.8 million for the three months ended March 31, 2023, compared to $10.5 million for the three months ended March 31, 2022. The increase was due to increased stock-related compensation expense and legal fees associated with our patent infringement suit against Pfizer. Net loss for the three months ended March 31, 2023 was $37.7 million, or a loss of $1.79 per diluted common share, compared to a”

ENANTA PHARMACEUTICALS INC entered into Royalty Purchase Agreement with OCM Life Sciences Portfolio LP, an investment vehicle of OMERS valued at $200 million (effective 2023-04-25).

“On April 25, 2023, Enanta Pharmaceuticals, Inc. and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans, entered into a Royalty Purchase Agreement (the “ Agreement ”), pursuant to which Enanta sold to OMERS 54.5% of Enanta’s royalty interest in respect of worldwide net sales of MAVYRET ® /MAVIRET ® (and any other royalty-bearing products that may contain glecaprevir). The purchase price paid to Enanta was $200 million.”

ENANTA PHARMACEUTICALS INC shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023 at the 2023-03-02 meeting.

“The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.”

ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2023-03-02 meeting.

“The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.”

ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved by 975,000 shares at the 2023-03-02 meeting.

“The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares.”

ENANTA PHARMACEUTICALS INC shareholders approved Election of Two Class I Directors at the 2023-03-02 meeting.

“The stockholders re-elected the following individuals as Class I directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Bruce L.A. Carter, Ph.D. 14,297,051 3,316,218 1,371,281 Jay R. Luly, Ph.D. 16,673,120 940,149 1,371,281”

ENANTA PHARMACEUTICALS INC reported fiscal first quarter ended December 31, 2022 results: revenue $23.6 million, net income $29.0 million, EPS a loss of $1.39 per diluted common share.

“Total revenue for the three months ended December 31, 2022 was $23.6 million and consisted primarily of $22.6 million of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET®, AbbVie’s eight-week treatment for chronic hepatitis C virus (HCV). For the three months ended December 31, 2021, total royalty revenue was $27.6 million on AbbVie’s sales of MAVYRET/MAVIRET. The decline is primarily a result of continued lower treated patient volumes due to the COVID-19 pandemic. Research and development expenses totaled $40.9 million for the three months ended December 31, 2022, compared to $48.5 million for the three months ended December 31, 2021. The decrease was primarily due to the timing of drug supply manufacturing and preclinical studies in the company’s virology program year over year. General and administrative expenses totaled $12.7 million for the three months ended December 31, 2022, compared to $9.5 million for the three months ended December 31, 2021. This increase was pri”

ENANTA PHARMACEUTICALS INC reported twelve months ended September 30, 2022 results: revenue $86.2 million, net income Net loss was $121.8 million, EPS loss of $5.91 per diluted common share. Guidance initiated.

“For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, general and administrative expenses were $45.5 million compared to $32.5 million in 2021. The increases in both periods were due primarily to additional headcount and stock compensation expense. Enanta recorded an income tax expense”

ENANTA PHARMACEUTICALS INC reported three months ended September 30, 2022 results: revenue $20.3 million, net income Net loss was $26.3 million, EPS loss of $1.27 per diluted common share. Guidance initiated.

“Total revenue of $20.3 million for the three months ended September 30, 2022, consisted of royalty revenue derived from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®, compared to royalty revenue of $23.6 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended Septe”